LAURA: Osimertinib Consolidation
LAURA: Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC

Released: June 04, 2024

Expiration: June 03, 2025

Activity

Progress
1
Course Completed